REGENXBIO Inc. filings document governance, operating results and material events for a biotechnology company developing AAV gene therapies. Recent 8-K disclosures include quarterly and annual results, FDA communications involving RGX-121 and RGX-111, and regulatory updates tied to a Biologics License Application and investigational new drug applications.
The filing record also covers collaboration and license matters, including an amendment to the AbbVie collaboration for surabgene lomparvovec and a settlement related to the GSK-REGENXBIO sublicense. Proxy materials describe board elections, stockholder meeting matters, executive compensation, equity awards and other governance disclosures for the Delaware corporation.
RGNX Rule 144 notice reporting a proposed sale of 43,206 shares of Common Stock tied to an Exercise of Stock Options, scheduled 07/01/2026. The filing also lists prior 10b5-1 sales by Stephen Pakola: 19,608 shares on 06/29/2026 for $216,560.60 and 15,309 shares on 05/11/2026 for $168,737.84.
REGENXBIO Inc. amends its Schedule TO to report updates to an Exchange Offer that permits certain non-executive employees to exchange eligible outstanding stock options for replacement options under the terms of the company’s Offer to Exchange dated June 3, 2026. The amendment includes communications, FAQs, and plan documents; other Schedule TO disclosures remain unchanged.
REGENXBIO Inc. reported that it earned a $100 million milestone payment from AbbVie after dosing the first patient in the Phase IIb/III NAAVIGATE trial of investigational gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy using suprachoroidal delivery. The payment is tied to REGENXBIO’s 2021 collaboration and license agreement with AbbVie and is expected to be received in July 2026. NAAVIGATE will evaluate a one-time gene therapy dose of 1.0x1012 genome copies per eye in approximately 135 U.S. participants with non-proliferative diabetic retinopathy, with a primary endpoint of more than a two-step improvement on the diabetic retinopathy severity scale at one year. REGENXBIO also plans to present long-term data from its ALTITUDE and wet AMD studies and to announce topline pivotal trial data for sura-vec in wet AMD with AbbVie in Q4 2026.
JPMorgan Chase & affiliates reported beneficial ownership of 2,279,362 shares of REGENXBIO Inc. The filing, an amendment to a Schedule 13G/A, shows those shares represent 4.4% of the outstanding common stock (CUSIP 75901B107). The report attributes 2,104,445 shares of sole voting power and 2,279,362 shares of sole dispositive power. Multiple JPMorgan entities are named as holders. The filing is signed by a JPMorgan vice president.
REGENXBIO Inc. filed a Schedule TO-I reporting an Offer to Exchange eligible employee stock options for replacement options. The exchange is limited to non-executive employees and options granted under the 2015 Equity Incentive Plan with grant dates before July 1, 2024 and an exercise price per share of at least $18.00. As of May 27, 2026, Eligible Options to purchase 2,915,945 shares were outstanding. Replacement Options will be granted under the 2025 Equity Incentive Plan and the number of shares underlying each Replacement Option will be determined using the applicable exchange ratio described in the Offer to Exchange.
REGENXBIO Inc. reported the results of its 2026 annual stockholder meeting and launched a stock option exchange program for non-executive employees. Stockholders elected three Class II directors to serve until the 2029 annual meeting and ratified PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026.
Stockholders also approved, on an advisory basis, the compensation of named executive officers and approved a Stock Option Exchange Program for non-executive employees, but did not approve a similar program for executive employees. On June 3, 2026, the company began the approved exchange program, allowing eligible non-executive employees to exchange underwater options with exercise prices at or above $18.00 for a reduced number of options with an exercise price set at fair market value after the offer period, which runs from June 3 to July 1, 2026. The company states the program is not expected to significantly change its stock compensation expense.
REGENXBIO Inc. director Daniel Tasse reported new equity awards. He received 9,807 shares of common stock through a time-based restricted stock unit grant, which will vest in full on May 29, 2027 if he remains in continuous service.
He was also granted stock options for 46,600 shares of common stock at an exercise price of $7.01 per share, vesting on May 29, 2027 and expiring on May 29, 2036. Following these awards, he directly holds 28,861 shares of common stock. These are compensation-related grants, not open-market purchases or sales.
REGENXBIO Inc. director David C. Stump reported equity compensation awards, not open-market purchases. He received 9,807 shares of common stock underlying a time-based restricted stock unit that will vest on May 29, 2027, subject to his continuous service to the company.
He was also granted stock options covering 46,600 shares of common stock at an exercise price of $7.01 per share, which vest on May 29, 2027 and expire on May 29, 2036. Following these awards, he holds 28,861 shares of common stock directly.
REGENXBIO Inc. director Jennifer Zachary reported equity awards from the company. She received 9,807 shares of common stock in the form of a time-based restricted stock unit award that will fully vest on May 29, 2027, subject to continued service. Following this grant, she directly holds 31,871 common shares. She was also granted stock options covering 46,600 shares of common stock at an exercise price of $7.01 per share, which will vest on May 29, 2027 and expire on May 29, 2036.
REGENXBIO Inc. director Kenneth T. Mills reported equity awards consisting of restricted stock units and stock options. On May 29, 2026, he received 9,807 shares of common stock through a time-based restricted stock unit award that carries no cash exercise price. These RSUs are scheduled to vest 100% on May 29, 2027, conditioned on his continuous service to the company. On the same date, he was also granted stock options covering 46,600 shares of common stock at an exercise price of $7.01 per share, which are likewise scheduled to vest on May 29, 2027, subject to continued service. Following the stock grant, Mills directly held 495,925 shares of REGENXBIO common stock.